Scale-Up and Manufacturing of Cell-Based Therapies IV

Poster List
(Nov 24, 2014)

1. **Comparability and standardisation of scalable automated hMSC and pluripotent cell culture**
   Peter Archibald, Loughborough University, United Kingdom

2. **Neo-organs - products that regenerate, repair or replace diseased and dysfunctional human organs and tissues**
   Deepak Jain, Tengion, Inc., USA

3. **Serum-free expansion, harvest and preservation of mesenchymal stem cells from a scalable microcarrier process**
   Thomas RJ Heathman, Loughborough University, United Kingdom

4. **From pilot scale to mass production: Bioreactors scale-up in cell therapy industry**
   Nadav Eshkol, Pluristem, Israel

5. **A new paradigm of commercial manufacturing for autologous cell therapy**
   Dolores Baksh, GE Healthcare, USA

6. **Going the extra mile: How do we move bioreactors into manufacturing?**
   Siddharth Gupta, Lonza Walkersville, USA

7. **Optimal agitation conditions for human MSC expansion on microcarriers in stirred-tank bioreactors**
   Céline Martin, Université de Lorraine, France

8. **CFD large eddy simulation of the hydrodynamics of stirred mini-bioreactors operating with stem cell culture mixing conditions**
   Marie-Laure Collignon, Université de Liège, Belgium

9. **Clinic to commercial: Developing Scalable single-use closed-system solutions for continuous cell therapy manufacturing success**
   Dominic M. Clarke, Charter Medical, USA

10. **Upstream expansion solutions for stem cells**
    Aletta C. Schnitzler, EMD Millipore, USA

11. **Scalable xeno-free culture system for human induced pluripotent stem cell expansion**
    Sara M. Badenes, Institute for Bioengineering and Biosciences, Portugal

12. **Downstream solutions for scaling allogeneic stem cells**
    Daniel Kehoe, EMD Millipore Corporation, USA

13. **Manufacturing set-up: Advancement and evolution of consumables for cell therapy production**
    Mark SJ Briggs, GE Healthcare, United Kingdom

14. **Scalable production of tissue engineered microunits for bone regeneration using bioactive glass microspheres and dynamic culture conditions**
    David De Silva-Thompson, University College London, United Kingdom
15. Integrated 3D bioprocessing for the expansion and recovery of a functional human MSC cell population with uncompromised regenerative potential
   Ioannis Papantoniou, KU Leuven, Belgium

16. Optimized manufacturing process to generate CAR-T cells for clinical trials
   Pradip Bajgain, Baylor College of Medicine, USA

17. Application of Geltrax as potential scaffold for cornea tissue engineering
   Shweta Kamthan, IIT Delhi, India

18. Autologous bone marrow derived mesenchymal stem cell therapy for cerebrovascular stroke
   Hala Gabr, Cairo University, Egypt

19. Scale up and manufacture of human mesenchymal stromal cells in a single use bioreactor system
   Ian Gaudet, Progenitor Cell Therapy, USA

20. Acellular matrices derived from pluripotent stem cells modulated tissue development
    Yan Li, Florida State University, USA

21. Characterizing the response of human cells to processing by membrane separation operations using an ultra scale-down methodology
    Maria Fernanda Masri, University College London, United Kingdom

22. Production of HIV-1 Gag-VLPs in 293 cells for protein delivery
    Bruno Gaillet, Université Laval, Canada

23. Harvesting culture-derived platelets with functional activity from blood stem and progenitor cells
    William M. Miller, Northwestern University, USA

24. Scale up of a hollow fiber bioreactor system for large scale cellular product manufacturing
    Kristina Fuerst, Terumo BCT, USA

25. Efficient expansion of human mesenchymal stem cells (hMSCs) on Corning® Enhanced Attachment microcarriers using a continuous agitation protocol.
    Jennifer Weber, Corning Incorporated, USA

26. Impact of allogeneic stem cell manufacturing decisions on cost of goods and process robustness
    Tania D. P. Chilima, University College London, United Kingdom

27. An automated, functionally closed system for down-stream processing of large-scale cellular product manufacturing
    Brian J. Nankervis, Terumo BCT, USA

28. A life cycle cost assessment of the cell production for clinicals in Japan
    Takuro Kamiya, Waseda University Academic Solutions Corporation, Japan

29. Assembly of hES cell clusters in cell cultivation bags
    Arvind Pradip, Novo Nordisk A/S, Denmark
30. Development of low-cost chromatographic alternatives to magnetic affinity cell sorting (MACS)
   Christine Mueller, University of Loughborough, United Kingdom

31. Three dimensional culture of human mesenchymal stem cell improves stem cell property via energy metabolism regulation
   Yijun Liu, Florida State University, USA

32. Data management in cell therapy development and manufacturing
   Hasan Saleheen, GE, USA

33. Engineered phosphate bioactive glass microcarriers for hBM-MSCs expansion and osteodifferentiation
   Carlotta Peticone, University College London, United Kingdom

34. Expansion of mesenchymal stem cell derived from umbilical cord matrix in a fixed bed and stirred tank bioreactor: A comparative study
   Amanda Mizukami, University of São Paulo, Brazil

35. Towards standardized functional release assays for cell therapy candidates for ischemic injury
   Fatumina Abukar, University College London, United Kingdom

36. Impact of culture strategy on transcriptomic and metabolic profiles of human pluripotent stem cells
   Margarida Serra, iBET/ITQB-UNL, Portugal

37. Metabolic profiling of stem cell-derived human neural cells by 13C-NMR spectroscopy
   Paula M. Alves, iBET/ITQB-UNL, Portugal

38. Novel 3D co-culture strategy for the establishment of highly functional human hepatic cell models in bioreactors
   Patrícia Alves, iBET, Portugal

39. Scale up and recovery of a gammaretroviral vector
   Timothy J. Langer, Kite Pharma, USA

40. Filtration methodologies for the concentration and washing of human mesenchymal stem cells
   Bárbara Cunha, ITQB-UNL/iBET, Portugal

41. Screening study of key process conditions for anchorage dependent stem cell cultivation in scale-down model of vertical-wheel bioreactors
   Daniel Giroux, PBS Biotech, Inc., USA

42. Manual vs. automated induced pluripotent stem cell bioprocessing: Process economics and optimisation
   Michael Jenkins, University College London, United Kingdom

43. An aqueous two-phase system strategy for the elimination of contaminating cell debris
   Mirna González-González, Tecnológico de Monterrey, Mexico

44. Human pluripotent stem cell expansion in the Xuri cell expansion system W25
   Brian M. Davis, GE Global Research, USA
45. **Process modeling: A critical tool for process evaluation and development**  
   Meagan O’Kane, Celgene Cellular Therapeutics, USA

46. **Production of recombinant AAV and scAAV vectors for alcoholism treatment: Inhibiting ALDH2 gene expression in human hepatoma cells**  
   Anamaria C. Sanchez, University of Chile, Chile

47. **Process characterization of a Placental-Derived cell therapy utilizing quality by design strategies in preparation for process validation**  
   Keith Wilson, Celgene Cellular Therapeutics, USA